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To the editor,
The underlying pathogenetic mechanisms of Sjögren
syndrome (SjS) have not been elucidated yet [1]. Leptin is a
glycosylated peptide structurally similar to some cytokines
[2]. Leptin has proinflammatory effects via various
mechanisms. It has been previously reported that serum
leptin levels increase in some autoimmune diseases and
that leptin levels are also associated with disease activity
[3, 4]. In addition, leptin and its receptor in the salivary
glands stimulate epithelial proliferation and modulate
the local immune system with their autocrine effects [5].
In this study, we assessed the presence of leptin in minor
salivary glands (MSG) of the patients with and without SjS.
Additionally, we evaluated the association between leptin
staining intensity and disease activity among patients with
SjS.
We included patients who underwent MSG biopsy
with the suspicion of SjS between 2013 and 2014. Among
these patients, those who met the 2012 American College
of Rheumatology Sjögren’s syndrome classification criteria
(6) and had at least 50 mononuclear cell infiltrates in a 4
mm2 minor salivary gland section were classified as the
SjS group. The rest of the patients who underwent MSG
biopsy but did not meet the histopathological and/or
clinical criteria for SjS were considered the control group.
Leptin staining was assessed by immunohistochemistry
(Bio-Rad AbDSerotec, Oxford, UK) in the stroma,
acinar and ductal epithelium, and staining intensities
were graded by a semiquantitative method; no staining
(score 0), mild (score 1), moderate (score 2), and diffuse
(score 3). Definitions of leptin staining intensities were
described as mild; focal staining of few cells in one focus,
moderate; mild staining in more than one focus, diffuse;
diffuse staining in all assessed sections (Figure 1). The
sum of leptin staining in all areas was defined as total
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leptin staining. The SjS group was divided into 3 groups
according to the focus scores (FS) (FS1: FS = 1, FS2: FS =
2, FS3: FS ≥ 3). In addition, patients’ disease activities were
assessed by EULAR Sjogren’s syndrome disease activity
index (ESSDAI) [7].
Visual (histograms, probability plots) and analytical
methods (Kolmogorov-Smirnov test) were used to analyze
the variables’ distribution and select the test method.
Descriptive analyses were presented as mean or median
according to their distribution patterns. A chi-square
test was used for univariate analyses to identify variables
associated with leptin staining and clinical features.
Patients’ disease activities were assessed by ESSDAI
[9]. The correlations between ESSDAI scores and leptin
staining intensities were analyzed using Spearman’s test. A
p value of <0.05 was considered statistically significant. No
imputation was performed for missing values. Statistical
analyses were done using the SPSS software v.20.
The study protocol was approved by the Local Ethics
Committee of Dr. Lütfi Kırdar Training and Research
Hospital – İstanbul.
The median age of the patients with SjS (n = 24) and
the control group (n = 19) were 49.5 (24–78) and 53 (31–
77), respectively. The mean ESSDAI score of the patients
was 1.67 ± 1.44. The patients’ demographic and clinical
characteristics and antibody test results are summarized in
Table 1. The FSs of the patients were 1 in 25% (n = 6/24),
2 in 50% (n = 12/25) and ≥3 in 25% (n = 6/24). Leptin
staining patterns of both groups were similar in acinar,
ductal, or stromal areas (p = 0.827). However, among
the patient group the proportion of patients with at least
intermediate leptin staining intensity in stromal (in FS1
group: 33%, in FS2 group: 25%, in FS3 group: 100%),
acinar (in FS1 group: 50%, in FS2 group: 33%, in FS3
group: 80%), and ductal (in FS1 group: 50%, in FS2 group:
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Figure 1. Examples for leptin staining patterns in minor salivary glands. a) Diffuse leptin staining (score 3) in acinar, ductal, and stromal
areas in a minor salivary gland (× 400 magnification). b) Moderate (score 2) leptin staining in acinar and ductal areas in and diffuse
leptin staining (score 3) in the stromal area in minor salivary gland (× 400 magnification). c) Diffuse leptin staining (score 3) in acinar
and ductal minor areas and mild (score1) leptin staining in the stromal area in a salivary gland. d) No leptin staining in acinar and ductal
areas and mild leptin staining (score 1) in the stromal area in minor salivary gland (× 200 magnification).

66%, in FS3 group: 100%) areas were higher in the patients
with FS3. There was a positive correlation between ESSDAI
and leptin staining scores in the acinar area (p < 0.05; r =
0.406) regardless of focus scores. However, the correlations
between disease activity and leptin staining in ductal areas
(p: 0.1; r: 0.334), in stromal areas (p: 0.1; r: 0.184), and total
leptin (p: 0.2; r: 0.268) staining was not significant.
We identified that majority of the patients in both
groups had leptin staining in acinar (92% and 84%,
respectively), ductal (94% and 84%, respectively), and
stromal areas (96% and 100%, respectively) of their MSGs.
Patients with higher FSs had significantly more intense
leptin staining patterns. The possible explanations for the
similar staining pattern in patients with an FS of ≤2 was
the insufficient number of patients (β error) or absolute
indifference. In contrast, a study by Erbasan F et al. argued
that leptin has no role in primary SjS due to similar
leptin staining patterns among patients with SjS and
healthy controls. However, they did not compare patients
according to the ESSDAI scores [8]. Thus, we still need
more robust data to identify whether leptin has an inciting
or prognostic role in pSS.
Limitations of our study were the lack of some clinical

characteristics and metabolic parameters which may affect
leptin metabolism and lack of leptin receptor staining
patterns in MSG biopsies, which together with leptin
staining could better define the role of leptin. Lack of
power analysis was another limitation.
In conclusion, leptin staining properties were similar
in both SjS and non-SjS groups. Additionally, the only
clinical significance of leptin density in the MSG was in
the acinar region.
Conflict of interest
The authors have no financial or competing interests.
Acknowledgement/Disclaimers/Conflict of interest
All authors declare no conflict of interest We received
funding support from Kartal Dr. Lutfi Kirdar City Hospital
research assistance department. Authors contributed to
writing this study and have approved the final version.
Ethical approval: This article does not contain any
studies with human participants performed by any of the
authors. The study protocol was approved by the Local
Ethics Committee of Dr Lutfi Kirdar Kartal City Hospital
(No: 89513307/1009/293-06.05.2014).

525

ERDOĞAN et al. / Turk J Med Sci
Table 1. Demographic, clinical features, and antibody results of patients.

Median age (range)
Sex (F/M)
Dry mouth, n/N (%)*
No
Yes
Dry eye, n/N (%)*
No
Yes
Arthralgia, n/N (%)*
No
Yes
Arthritis, n/N (%)*
No
Yes
Salivary gland swelling, n/N (%)*
No
Yes
Vasculitic skin rash, n/N (%)*
No
Yes
Raynaud, n/N (%)*
No
Yes
Fatigue, n/N (%)*
No
Yes
Proteinuria, n/N (%)*
No
Yes
Rheumatoid factor
Negative, n/N (%)
Positive, n/N (%)
Unknown, n/N (%)
Antinuclear antibody
Negative, n/N (%)
Positive, n/N (%)
Unknown, n/N (%)
Anti SS-A
Negative, n/N (%)
Positive, n/N (%)
Unknown, n/N (%)
Anti SS-B
Negative, n/N (%)
Positive, n/N (%)
Unknown, n/N (%)

Patients with pSS
(n = 24)

Patients without pSS
(n = 19)

49.5 (24–78)
24/0

53 (31–77)
17/2

8/24 (33)
13/24 (54)

9/19 (47)
9/19 (47)

6/24 (25)
16/24 (67)

9/19 (47)
9/24 (47)

11/24 (46)
12/24 (50)

10/19 (53)
8/19 (42)

19/24 (79)
4/24 (17)

16/19 (84)
2/19 (11)

20/24 (83)
2/24 (8)

17/19 (90)
1/19 (5)

17/24 (71)
5/24 (21)

14/19 (74)
4/19 (21)

18/24 (75)
4/24 (17)

17/19 (89)
1/19 (5)

16/24 (67)
6/24 (25)

15/19 (79)
3/19 (16)

22/24 (92)
1/24 (4)

15/19 (79)
1/19 (5)

16/24 (67)
6/24 (25)
2/24 (8)

10/19 (53)
2/19 (11)
7/19 (37)

0,681**

13/24 (54)
8/24 (33)
3/24 (13)

10/19 (53)
6/19 (32)
3/19 (16)

0,970

10/24 (42)
3/24 (13)
11/24 (46)

12/19 (63)
4/19 (21)
3/19 (16)

1**

12/24 (50)
1/24 (4)
11/24 (46)

12/19 (63)
1/19 (5)
6/19 (32)

1**

p value
0,732
0,189**
0,455

0,14

0.756**

0.679**

1 **

1**

0,355**

0,476**

1**

*Absolute ratios and numbers of patients presented without correction for missing. **Fisher’s Exact Test.
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